Sorry, you need to enable JavaScript to visit this website.
  • share

Looking for Acute
For adults and children 12 years of age and older who have taken corticosteroids and they did not work well enough

Advocacy Resources

What other support and resources are available for people with chronic graft-versus-host disease?

If you are living with chronic graft-versus-host disease (GVHD), or caring for someone who is, it’s helpful to know that you’re not alone. These organizations offer helpful educational information, support services, and other resources that can complement those provided by your Healthcare Professional.

For more information, click on each link.

Incyte Corporation is not affiliated with these organizations but may have provided funding for some of their educational programs. This is not a complete list of organizations within the GVHD community and should not be considered an endorsement by Incyte of any particular organization listed.



Be the Match®

Be the Match Patient Support Center offers free support and resources for anyone diagnosed with a blood cancer or blood disorder. They can help patients get answers about the transplant process, cope with uncertainty, access financial grants, find clinical trials, and connect with others who have been through transplant.


Phone: 888-999-6743

Blood & Marrow Transplant Information Network (BMT InfoNet)

BMTInfoNet offers a wide array of services for transplant patients and their loved ones, including: easy-to-understand information about what to expect before, during, and after transplant surgery; a robust video learning library with health experts; counseling resources and workshops that can help with medical, emotional, and financial challenges; and support services that range from one-on-one peer phone calls to an online Facebook group for patients, family, and caregivers.


Phone: 847-433-3313 | Toll Free: 888-597-7674

National Bone Marrow Transplant Link (nbmtLINK)

The nbmtLINK is a nonprofit organization dedicated to helping patients, families, and caregivers cope with the social and emotional challenges of stem cell transplant. They connect people to a wide array of resources and also offer vital educational information from health experts and transplant survivors via their website. Free programs include telephone call-in Lunch & Learns, award-winning resource books, webinars, podcasts, blog articles shared by patients and caregivers, and a Second Birthdays recognition program. Personalized support is available through a licensed staff social worker and their Peer Support on Call Mentor Program, which allows patients and loved ones to connect by phone with people who have been through the transplant experience.


Phone: 800-LINK-BMT (800-546-5268)

Graphic of a woman with a headset, sitting at a desk, in front of a computer

Already taking Jakafi? IncyteCARES for Jakafi is a patient support program helping eligible patients with access and support.

Learn More

Image of a grey-haired woman smiling

Help others managing chronic GVHD.

Share your story and insights by joining the Ambassadors for Jakafi program.

Learn More







Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech.

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing.

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.